What development phase is TECHNETIUM BICISATE in?

TECHNETIUM BICISATE is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

TECHNETIUM BICISATE

FDA-approved approved Small molecule Quality 2/100

TechneTium Bicisate is a marketed radiopharmaceutical agent with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and revenue generation, though specific figures are not disclosed. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	TECHNETIUM BICISATE
Modality	Small molecule
Phase	FDA-approved
First approval	1994

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Ictal SPECT With Intra-arterial Injection (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results